The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

T-cell skin lymphomas are more common than B-cell skin lymphomas. Cutaneous T-cell lymphoma (CTCL) occurs when a mutation causes the cell to divide too quickly and stay alive too long. The ...

Citius Oncology, Inc. ("Citius Oncology" or the "Company") , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported ...

See a doctor who has experience with it. You’ll find dermatologists who have experience with cutaneous T-cell lymphoma at Find a Dermatologist. Click on "Filters". Select "Any condition" and choose ...

Intravascular large B-cell ... biopsy and skin biopsy from positive skin lesions or random skin biopsy (RSB) (90). The liquid biopsy has also been reported as a promising method for diagnosing IVLBCL ...

The phase 3 FLASH (NCT02448381) study evaluating SGX301 (HyBryte) has shown promising results, with over 70% of patients with early-stage cutaneous T-cell lymphoma (CTCL ... is topically applied to ...

EBV+ diffuse large B-cell lymphomas, and mastocytosis. In the context of skin lymphomagenesis, a type 2 immune profile is typical of mycosis fungoides and Sézary syndrome, the most frequent subtypes ...

T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...